Skip to main content

Table 5 Relationship between baseline Lp-PLA2 and gender, smoking, hypertension, diabetes, and ease of treatment

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Parameter Lp-PLA2 (ng/ml) t-test or ANOVA
t or F p
Gender Male (n = 55) 358.018 ± 77.133 5.832 <0.001
Female (n = 35) 271.8 ± 51.467
Smoking Smoker (n = 18) 444.833 ± 26.425 10.83 <0.001
Non-smoker (n = 72) 294.403 ± 57.237
Hypertension Hypertensive (n = 15) 396.8 ± 69.548 4.17 <0.001
Normotensive (n = 75) 310.027 ± 74.298
Diabetes Diabetic (n = 7) 398 ± 51.095 5.171 0.008† D&P 0.440
Pre-diabetic (n = 13) 353.923 ± 86.238 D&N 0.015
Non-diabetic (n = 70) 311.671 ± 76.597 P&N 0.167
Ease of treatment Easy to treat (n = 45) 301.444 ± 78.506 −2.837 0.006
Difficult to treat (n = 45) 347.533 ± 75.582
  1. †ANOVA (F) test, post hoc test
  2. Abbreviations: n, number; Lp-PLA2, lipoprotein-associated phospholipase A2; D, diabetic; P, pre-diabetic; N, non-diabetic